Understanding Treatment Options for CLL
- A BTK (Bruton tyrosine kinase) inhibitor is one of the most common treatments for chronic lymphocytic leukemia, or CLL. It works by blocking a protein the cancer cells rely on to grow.
- There is an older version and newer therapies. Ibrutinib (Imbruvica) is the original. Acalabrutinib (Calquence) and zanubrutinib (Brukinsa) came later. Research suggests the latter tend to cause fewer serious side effects, especially problems with the heart’s rhythm.
- These targeted drugs are usually taken every day, for as long as they keep working. However, there is also a different kind of CLL treatment that is given for a set stretch of time and then stopped.
- There’s no single “best” drug. The right fit depends heavily on the rest of your health, which is why this is a decision you make with your doctor, not on your own.
Here’s the simple version of how it works.
What a BTK Inhibitor Actually Does
Read MoreOlder versus Newer Drugs for CLL
Not all BTK inhibitors are the same. There’s a first, older generation and a second, newer one.
“We have an older generation called ibrutinib that we’ve been using for the last 10 years, and we have a newer second generation called acalabrutinib and zanubrutinib,” Dr. Alkharabsheh says. “Those can be done alone or in combinations.”
The newer drugs were built to hit BTK more precisely. That matters because ibrutinib (brand name Imbruvica), the original, can also nudge other parts of the body it wasn’t aiming for and that’s where some of its side effects come from.
One large research review that pooled results from thousands of patients found the newer drugs work at least as well as the older one. And in some situations a little better, while causing fewer serious side effects overall. The clearest gap was in the heart: a rhythm problem called atrial fibrillation (an irregular, often fast heartbeat) showed up roughly twice as often with the older drug. If you already have heart trouble, that’s not a small detail.
A Pill You Keep Taking, or a Treatment That Ends
There’s another difference patients almost always ask about: how long am I on this?
BTK inhibitors are usually what doctors call a continuous treatment. You keep taking the pill for as long as it’s holding the disease back. There’s another type of drug that works differently, and Dr. Alkharabsheh explains where it fits.
“The other class of medication, we call it BCL-2, is combined with a monoclonal antibody called obinutuzumab,” he says.
A BCL-2 inhibitor blocks a different protein, one that cancer cells use to avoid dying; the main drug in this group is called venetoclax. A monoclonal antibody is a lab-made protein that helps your immune system spot and attack cancer cells. Obinutuzumab (brand name Gazyva) is one of those antibodies.
The key difference is time. “One of them is a continuous treatment. The other one is a fixed duration,” he says. “So we treat the patient for one year, and then we stop.”
For some people, a treatment with a finish line is a relief. For others, staying on a daily pill that’s clearly working feels safer. Neither answer is wrong.
What About Combining These Therapies?
Doctors have been studying whether using both types of drug together might work even better.
“Now, newer combinations are being done between both of those classes of medications, but those are still in clinical trials,” he said. “And also we have results of several other studies that showed excellent activity.”
In February 2026, the U.S. Food and Drug Administration (FDA) approved a combination of a BTK inhibitor and a BCL-2 inhibitor (acalabrutinib, brand name Calquence, plus venetoclax, also known as Venclexta) for adults with previously untreated CLL.
No One-Size-Fits-All Treatment For CLL
This is where it gets personal, and it’s the reason there’s no one-size-fits-all answer.
Because these drugs work well, they’re a standard choice for a lot of people with CLL — both those starting treatment for the first time and those whose disease came back or stopped responding to an earlier treatment (doctors call that “relapsed or refractory”). But picking the specific drug comes down to you: your heart, your other health conditions, the medicines you already take, and what you want your treatment to look like day to day.
Dr. Alkharabsheh describes it as a matching process.
“We need to match the side effects of these agents to the patient comorbidities to make sure that they tolerate the treatment with minimal adverse events,” he says. Comorbidities is the medical word for the other health conditions you’re living with alongside the cancer.
Careful Decisions With Your Care Team
In practice, that matching really does change the plan. Because BTK inhibitors can affect the heart’s rhythm and raise the risk of bleeding, doctors often steer away from them for someone who already has certain heart problems, a history of serious bleeding, or who takes blood-thinning medicine. For those patients, the fixed-duration option is frequently the better fit. It’s a good example of why the same diagnosis can lead to two very different treatment plans.
He also points out that the conversation doesn’t end once treatment starts. Sometimes the goal shifts toward stopping, if the disease is deeply under control: what doctors call remission. That, he says, is something to “discuss with the patient about when to stop treatment if we can achieve deeper remission.”
If there’s one thing to take away from all this, it’s that the drug is only half the decision. The other half is the honest back-and-forth with your care team about your body and your life. Bring your questions. Ask why one option is being suggested over another. This is your treatment, and you have every right to understand each piece of it.
Learn more about SurvivorNet's rigorous medical review process.
